Relief of bleedingdichotomic · patients with uterine fibroids
Mifepristone (5 mg/day/6 months) showed no clear difference in relief of bleedingdichotomic compared with placebo (low certainty).
1 finding from 1 review
Leiomyoma volume (mL) · patients with uterine fibroids
1 finding from 1 review
Uterine volume (cm³) · patients with uterine fibroids
1 finding from 1 review
Treatment failure Need for additional treatment · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in treatment failure Need for additional treatment compared with SCS treatment (moderate certainty).
1 finding from 1 review
Relapse New acute exacerbation or COPD‐related admission · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in relapse New acute exacerbation or COPD‐related admission compared with SCS treatment (moderate certainty).
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in adverse drug effect—hyperglycaemia compared with SCS treatment (moderate certainty).
1 finding from 1 review
Adverse drug effects Gastrointestinal tract bleeding, symptomatic gastrointestinal reflux, symptoms of congestive heart failure or ischaemic heart disease, sleep disturbance, fractures, depression · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in adverse drug effects Gastrointestinal tract bleeding, symptomatic… compared with SCS treatment (low certainty).
1 finding from 1 review
All‐cause mortality · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in mortality compared with SCS treatment (moderate certainty).
1 finding from 1 review
FEV1 · exacerbations of COPD
1 finding from 1 review
QoL · exacerbations of COPD
1 finding from 1 review
Leiomyoma volume (mL) · patients with uterine fibroids
1 finding from 1 review
Uterine volume (cm³) · patients with uterine fibroids
1 finding from 1 review
Relief of bleedingdichotomic · patients with uterine fibroids
Mifepristone (10 mg/day/3 months) may leads to higher relief of bleedingdichotomic compared with placebo (low certainty).
1 finding from 1 review
Relief of pelvic paindichotomic · patients with uterine fibroids
Mifepristone (10 mg/day/3 months) showed no clear difference in relief of pelvic paindichotomic compared with placebo (low certainty).
1 finding from 1 review
Relief of dysmenorrhoeadichotomic · patients with uterine fibroids
Mifepristone (10 mg/day/3 months) may leads to higher relief of dysmenorrhoeadichotomic compared with placebo (low certainty).
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous and mucocutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found